Legros JJ, Ansseau M. - Neurohypophyseal peptides and psychopathology. Prog Brain Res, 1992, 93, 455-461.
Scantamburlo G, Ansseau M, Legros J.J. - Neurophysins in mood disorders. Neuropeptide Research Trends. 2007. Ed : Bernice A. Levine, Nova Science Publishers, Inc.
Kosfeld M, Heinrichs M, Zak PJ, et al. - Oxytocin increases trust in humans. Nature, 2005, 435, 673-676.
Legros JJ. - Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones? Psychoneurol, 2001, 26, 649-655.
Legros, JJ, Chiodera P, Demey-Ponsart E. - Inhibitory influence of exogenous oxytocin on adrenocorticotropin secretion in normal humansubjects. J Clin Endocrinol Metab, 1982, 55, 1035-1039.
Scott LV, Dinan TG. - Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sciences. 1998, 62, 1985-1998.
Scott LV, Dinan TG. - Anatomy of melancolia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat, 2005, 207, 259-264.
Holsboer F, Barden N. - Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev. 1996, 17, 187-205.
Purba J, Hoogendijk W, Hofman M, Swaab D. - Increased numbers of vasopressin- and oxytocin-containing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry. 1996, 53, 137-143.
Gold P, Goodwin F, Reus V. - Vasopressin in affective illness. Lancet. 1978, 1, 1233-1236.
Zhou JN, Riemersma R, Unmehopa U, et al. - Alterations in arginine-vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry, 2001, 58, 655-662.
van Londen L, Goedkoop JG, van Kempen GM, et al. - Plasma levels of arginine-vasopressin elevated in patients with major depression. Neuropsychol, 1997, 17, 284-292.
Scantamburlo G, Hansenne M, Fuchs S, et al. - AVP-and OT-neurophysins response to apomorphine and clonidine stimulation in major depression. Psychoneurol, 2005, 30, 839-845.
Pitchot W, Scantamburlo G, Pinto E, et al. - Vasopressin-Neurophysin and DST in major depression : relation with suicidal behavior. J Psychiatr Res, 42, 2007.
Scantamburlo G, Hansenne M, Fuchs S, et al. - Plasma oxytocin levels and anxiety in patients with major depression. Psychoneurol, 2007, 32, 407-410.
Heuser I, Bissette G, Dettling M, et al. - Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls : response to amitriptyline treatment. Depress Anxiety, 1998, 8, 71-79.
Uvnas-Moberg K, Bjokstrand E, Hillegaart V, Ahlenius S. - Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacol, 1999, 142, 95-101.
Scantamburlo G, Pitchot W, Pinto E, et al. - Therapeutic utilisations of Vasopressin and Oxytocin in mood disorders. Recent Patents on Endocrine, Metabolic & Immune. Drug Disc, 2007, 1, 157-161.
Serradeil-Le Gal C, Wagnon J, Simiand J, et al. - Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther, 2002, 300, 1122-1230.
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. - Social support and oxytocin inetract to suppress cortisol and subjective responses to psychological stress. Biol. Psychiatry, 2003, 54, 1389-1398.
van West D, Del-Favero J, Aulchenko Y, et al. - A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry, 2004, 9, 287-292.
